---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004087"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:04:37.357436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022

## Summary
- Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).
- Cash and investments $240.2M as of Dec 31, 2021; cash runway into 2H 2023.
- R&D expenses $63.4M full year; G&A $23.0M; non-cash stock-based comp $14.5M.
- NKX101 Phase 1 monotherapy data (AML/MDS) expected 1H 2022; NKX019 data in 2022.
- NKX101 received FDA orphan drug designation for AML; protocol amendments filed.

## SEC filing metadata
- accession: 0000950170-22-004087
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/0000950170-22-004087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/nktx-20220317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004087
- JSON: https://secwatch.observer/filing/0000950170-22-004087.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.